Jul 3 |
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
|
Jul 1 |
Codexis to sell Pompe, Fabry assets to Crosswalk Therapeutics
|
Jul 1 |
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
|
Jun 24 |
Investors in Codexis (NASDAQ:CDXS) have unfortunately lost 88% over the last three years
|
Jun 12 |
Syntis Bio launches oral therapies for metabolic diseases
|
May 22 |
Codexis to Participate in Jefferies Global Healthcare Conference
|
May 20 |
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
|
May 14 |
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
|
May 4 |
Codexis First Quarter 2024 Earnings: Beats Expectations
|
May 3 |
Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call Transcript
|